Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicatertide in Lumbar Degenerative Disc Disease
NCT05516992Phase 3Active, not recruiting
- Sponsor
- Spine BioPharma, Inc.
- Start
- Aug 2022
- Primary completion
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of vicatertide in lumbar degenerative disc syndrome (LDDS), sponsored by Spine BioPharma, Inc.. Started Aug 2022; status: active, not recruiting.
02
Drugs
vicatertide
03
Conditions
lumbar degenerative disc syndrome (LDDS)
Beyond the preview
Go deeper on NCT05516992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516992.